Literature DB >> 1618598

The macroscopic and microscopic pharmacology of monoclonal antibodies.

J N Weinstein1, W van Osdol.   

Abstract

When monoclonal antibodies directed against tumor-associated antigens are injected intravenously, they sometimes fail to distribute uniformly in the substance of a tumor. To understand the possible reasons, it is necessary to consider both macroscopic and microscopic features of the pharmacology. We have analyzed antibody penetration into microscopic primary tumors and metastases by melding together information on the global pharmacokinetics, convective and diffusive transport across the blood capillary wall, diffusion through the tumor interstitial space, antigen - antibody interaction, metabolism, and lymphatic outflow. This analysis predicts that the very fact of successful binding will decrease the homogeneity of distribution. We believe that this "binding site barrier" constitutes major challenges to the molecular design of next-generation antibodies and also to the design of many other types of ligands for use in treatment of solid tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618598     DOI: 10.1016/0192-0561(92)90176-l

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  9 in total

1.  Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery.

Authors:  Deirdre P McIntosh; Xiang-Yang Tan; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 2.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

Review 3.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

4.  Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Authors:  Daniel A Vallera; Hua Chen; Andrew R Sicheneder; Angela Panoskaltsis-Mortari; Elizabeth P Taras
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

5.  Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.

Authors:  Vladimir Vexler; Li Yu; Chandrasena Pamulapati; Rosario Garrido; Hans Peter Grimm; Priya Sriraman; Sandhya Bohini; Michael Schraeml; Usha Singh; Michael Brandt; Stefan Ries; Han Ma; Klaus Klumpp; Changhua Ji
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

Review 6.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

Authors:  Nicolas Bertrand; Jun Wu; Xiaoyang Xu; Nazila Kamaly; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

Review 7.  Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

Authors:  Xing Jing; Yan Hou; William Hallett; Chandrahas G Sahajwalla; Ping Ji
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

8.  Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model.

Authors:  Takahito Nakajima; Kohei Sano; Peter L Choyke; Hisataka Kobayashi
Journal:  Theranostics       Date:  2013-04-23       Impact factor: 11.556

9.  Endogenous antibodies for tumor detection.

Authors:  Barrie S Rich; Joshua N Honeyman; David G Darcy; Peter T Smith; Andrew R Williams; Irene Isabel P Lim; Linda K Johnson; Mithat Gönen; Joel S Simon; Michael P LaQuaglia; Sanford M Simon
Journal:  Sci Rep       Date:  2014-05-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.